OPKO Health, Inc. (OPK) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
26/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinOPK / S&P 31.58% / 15.20% |
LoseOPK / S&P -11.47% / 15.00% |
LoseOPK / S&P -62.50% / 50.40% |
| 2026-Q11/3 |
LoseOPK / S&P -9.52% / -4.33% |
LoseOPK / S&P -15.71% / 11.30% |
WinOPK / S&P 350.00% / 27.70% |
| 2025-Q40/3 |
LoseOPK / S&P -18.71% / 2.65% |
LoseOPK / S&P -14.90% / 9.00% |
LoseOPK / S&P OPK unavailable / 13.40% |
| 2025-Q31/3 |
WinOPK / S&P 17.42% / 8.12% |
LoseOPK / S&P -9.75% / 4.61% |
LoseOPK / S&P OPK unavailable / 13.45% |
| 2025-Q20/3 |
LoseOPK / S&P -20.48% / 10.94% |
LoseOPK / S&P -7.31% / 4.83% |
LoseOPK / S&P OPK unavailable / 10.63% |
| 2025-Q11/3 |
WinOPK / S&P 12.93% / -4.27% |
LoseOPK / S&P -13.78% / 4.98% |
LoseOPK / S&P OPK unavailable / 10.57% |
| 2024-Q40/3 |
LoseOPK / S&P -1.34% / 2.41% |
LoseOPK / S&P -17.41% / 5.25% |
LoseOPK / S&P OPK unavailable / 6.15% |
| 2024-Q31/3 |
WinOPK / S&P 19.20% / 5.89% |
LoseOPK / S&P -17.94% / 5.89% |
LoseOPK / S&P OPK unavailable / 6.11% |
| 2024-Q20/3 |
LoseOPK / S&P 4.17% / 4.28% |
LoseOPK / S&P -17.48% / 5.38% |
LoseOPK / S&P OPK unavailable / 5.12% |
| 2024-Q10/3 |
LoseOPK / S&P -20.53% / 10.56% |
LoseOPK / S&P -12.38% / 5.71% |
LoseOPK / S&P OPK unavailable / 5.59% |
| 2023-Q40/3 |
LoseOPK / S&P -5.63% / 11.69% |
LoseOPK / S&P -14.01% / 6.81% |
LoseOPK / S&P OPK unavailable / 7.78% |
| 2023-Q30/3 |
LoseOPK / S&P -26.27% / -3.27% |
LoseOPK / S&P -28.95% / 7.52% |
LoseOPK / S&P OPK unavailable / -5.03% |
| 2023-Q21/3 |
WinOPK / S&P 48.63% / 8.74% |
LoseOPK / S&P -39.14% / 9.50% |
LoseOPK / S&P OPK unavailable / -8.57% |
| 2023-Q12/3 |
WinOPK / S&P 16.80% / 7.50% |
LoseOPK / S&P -41.46% / 10.77% |
WinOPK / S&P 105.26% / -15.69% |
| 2022-Q41/3 |
LoseOPK / S&P -33.86% / 7.56% |
LoseOPK / S&P -43.42% / 11.88% |
WinOPK / S&P 650.00% / -17.99% |
| 2022-Q30/3 |
LoseOPK / S&P -25.30% / -4.88% |
LoseOPK / S&P -34.68% / 13.47% |
LoseOPK / S&P -509.09% / -1.41% |
| 2022-Q20/3 |
LoseOPK / S&P -26.45% / -16.10% |
LoseOPK / S&P -25.34% / 13.71% |
LoseOPK / S&P -372.73% / 11.04% |
| 2022-Q10/3 |
LoseOPK / S&P -28.48% / -4.60% |
LoseOPK / S&P -11.89% / 15.97% |
LoseOPK / S&P -200.00% / 42.23% |
| 2021-Q42/3 |
WinOPK / S&P 31.78% / 11.03% |
WinOPK / S&P 23.64% / 15.00% |
LoseOPK / S&P OPK unavailable / 96.40% |
| 2021-Q31/3 |
LoseOPK / S&P -9.88% / 0.58% |
WinOPK / S&P 60.34% / 10.77% |
LoseOPK / S&P OPK unavailable / 69.42% |
| 2021-Q21/3 |
LoseOPK / S&P -5.59% / 8.55% |
WinOPK / S&P 97.80% / 6.58% |
LoseOPK / S&P OPK unavailable / 51.81% |
| 2021-Q12/3 |
WinOPK / S&P 8.61% / 6.17% |
WinOPK / S&P 98.56% / -1.06% |
LoseOPK / S&P OPK unavailable / 7.39% |
| 2020-Q41/3 |
LoseOPK / S&P 7.05% / 12.15% |
WinOPK / S&P 59.15% / -3.72% |
LoseOPK / S&P OPK unavailable / -33.42% |
| 2020-Q31/3 |
LoseOPK / S&P 8.21% / 8.93% |
WinOPK / S&P 29.53% / -2.04% |
LoseOPK / S&P OPK unavailable / -27.10% |
| 2020-Q22/3 |
WinOPK / S&P 154.48% / 20.54% |
WinOPK / S&P 4.92% / -0.46% |
LoseOPK / S&P OPK unavailable / -27.11% |
| 2020-Q11/3 |
WinOPK / S&P -8.84% / -19.60% |
LoseOPK / S&P -6.98% / 3.47% |
LoseOPK / S&P OPK unavailable / -14.75% |
| 2019-Q40/3 |
LoseOPK / S&P -29.67% / 9.07% |
LoseOPK / S&P -8.92% / 5.36% |
LoseOPK / S&P OPK unavailable / 2.99% |
| 2019-Q30/3 |
LoseOPK / S&P -14.34% / 1.70% |
LoseOPK / S&P -3.22% / 5.02% |
LoseOPK / S&P OPK unavailable / 0.21% |
| 2019-Q20/3 |
LoseOPK / S&P -6.51% / 4.30% |
LoseOPK / S&P -0.55% / 6.64% |
LoseOPK / S&P OPK unavailable / 8.65% |
| 2019-Q10/3 |
LoseOPK / S&P -13.29% / 13.65% |
LoseOPK / S&P 0.34% / 8.12% |
LoseOPK / S&P OPK unavailable / 14.29% |
| 2018-Q41/3 |
WinOPK / S&P -13.01% / -13.52% |
LoseOPK / S&P 6.69% / 9.05% |
LoseOPK / S&P OPK unavailable / 18.23% |
| 2018-Q30/3 |
LoseOPK / S&P -26.38% / 7.71% |
LoseOPK / S&P -0.97% / 10.21% |
LoseOPK / S&P OPK unavailable / 19.06% |
| 2018-Q21/3 |
WinOPK / S&P 48.26% / 3.43% |
LoseOPK / S&P -6.55% / 9.03% |
LoseOPK / S&P OPK unavailable / 14.46% |
| 2018-Q10/3 |
LoseOPK / S&P -35.31% / -0.76% |
LoseOPK / S&P -9.52% / 7.68% |
LoseOPK / S&P OPK unavailable / 12.46% |
| 2017-Q40/3 |
LoseOPK / S&P -28.57% / 6.64% |
LoseOPK / S&P -16.94% / 7.03% |
LoseOPK / S&P OPK unavailable / 13.82% |
| 2017-Q30/3 |
LoseOPK / S&P 4.26% / 4.48% |
LoseOPK / S&P -23.22% / 5.68% |
LoseOPK / S&P OPK unavailable / 17.57% |
| 2017-Q20/3 |
LoseOPK / S&P -17.75% / 3.09% |
LoseOPK / S&P -7.20% / 4.83% |
LoseOPK / S&P OPK unavailable / 17.74% |
| 2017-Q11/3 |
LoseOPK / S&P -13.98% / 6.07% |
WinOPK / S&P 40.16% / 3.67% |
LoseOPK / S&P OPK unavailable / 13.32% |
| 2016-Q41/3 |
LoseOPK / S&P -12.18% / 3.82% |
WinOPK / S&P 127.25% / 2.09% |
LoseOPK / S&P OPK unavailable / 7.05% |
| 2016-Q32/3 |
WinOPK / S&P 13.38% / 3.85% |
WinOPK / S&P 407.04% / 0.20% |
LoseOPK / S&P OPK unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | OPK total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 8.70% | 20.78% |
| Annualized return | 8.70% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | OPK total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -61.04% | 83.14% |
| Annualized return | -17.18% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | OPK total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -83.85% | 319.30% |
| Annualized return | -16.67% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |